Meeder Advisory Services’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-3,283
Closed -$224K 618
2025
Q1
$224K Sell
3,283
-848
-21% -$69.2K 0.01% 523
2024
Q4
$321K Sell
4,131
-1,530
-27% -$113K 0.02% 432
2024
Q3
$380K Sell
5,661
-1,620
-22% -$133K 0.02% 396
2024
Q2
$826K Buy
7,281
+1,986
+38% +$251K 0.06% 250
2024
Q1
$734K Buy
5,295
+476
+10% +$59.8K 0.07% 226
2023
Q4
$598K Sell
4,819
-63
-1% -$6.44K 0.07% 242
2023
Q3
$455K Sell
4,882
-2,683
-35% -$302K 0.06% 276
2023
Q2
$972K Buy
7,565
+622
+9% +$75.2K 0.1% 163
2023
Q1
$807K Buy
6,943
+195
+3% +$21.8K 0.09% 193
2022
Q4
$764K Buy
+6,748
New +$741K 0.1% 196

Other funds holding DXCM

Meeder Advisory Services's DXCM Position: Q2 2025 in Review

Meeder Advisory Services sold out of DexCom (DXCM) in Q2 2025, closing a stake of 3,283 shares — an estimated $224K sold.

Meeder Advisory Services first reported a position in DXCM in Q4 2022 and held it in 10 quarters. The position peaked at $972K in Q2 2023. 939 funds tracked by Wall St. Rank hold DXCM as of Q2 2025.

  • Meeder Advisory Services reported no remaining DexCom position as of Q2 2025 after selling out during the quarter.
  • Meeder Advisory Services sold 3,283 DexCom shares in Q2 2025, an estimated $224K.
  • Meeder Advisory Services first reported a position in DexCom in Q4 2022 and held it in 10 quarters.
  • Meeder Advisory Services's DexCom position peaked at $972K in Q2 2023.
  • 939 funds tracked by Wall St. Rank held DexCom as of Q2 2025.

Based on Meeder Advisory Services's 13F filing for Q2 2025, filed 7 Aug 2025.